Clinical Trial Update: A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. [Phase 1, Phase 2]

View source ↗

Summary

AstraZeneca is conducting a study to evaluate safety, pharmacokinetics, pharmacodynamics, and efficacy of AZD5492, a CD20-targeting T cell-engager, in relapsed/…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancies

Drugs mentioned

• AZD5492 (AZD5492)

Snippet

Sponsor: AstraZeneca | Conditions: B-cell Malignancies | Phase 1, Phase 2 | Status: RECRUITING